Date: 2016-02-05
Type of information: Financing round
Company: Tivorsan Pharmaceuticals (USA - RI)
Investors:
Amount: $1.8 million
Funding type: financing round
Planned used: The financing will be used to fund research and development of Tivorsan’s lead compound, recombinant human Biglycan, for the treatment of Duchenne muscular dystrophy and other neuromuscular disorders, and for working capital and general corporate purposes. In addition, the financing will serve as a bridge to the Company’s proposed Series D convertible preferred financing, which is expected to close in the second quarter.
Others: * On February 5, 2016, Tivorsan Pharmaceuticals announced that it has raised approximately $1.8 million in private financing from a leading institutional investor, as well as other existing and new accredited investors. T.R. Winston & Company served as placement agent to Tivorsan in the financing.
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
